Valion Bio opened lower at $0.50, compared with its previous close of $0.50. In the last trading session, the stock traded between $0.49 and $0.52. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Valion Bio is now worth
$ 0.01
Resulting in a loss of
$ 99.99 (99.99%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.01 (+1.23%)
Day High
$0.52
Day Low
$0.49
Day Open
$0.50
Prev Close
$0.50
Volume
82,641
1W Return
-0.59%
1M Return
-69.70%
3M Return
67.43%
6M Return
-54.14%
1Y Return
-77.53%
Fundamentals
Market Cap ($ Mn)
1
PE Ratio
-
PB Ratio
0.12
PEG Ratio
-
ROE
-126.29%
ROCE
-85.90%
EPS (TTM)
$-44.25
Investment Returns
1 Week
-0.59%
1 Month
-69.70%
3 Months
67.43%
6 Months
-54.14%
9 Months
-41.33%
Financials
Quarterly
All values in $ Mn
0.1
Mar 25
0.1
Jun 25
0.1
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
11Nov
Valion Bio to discuss Entolimod for troops at Baird conference
Valion Bio to attend RW Baird's 2026 National Security Conference on November 17, 2026. Top-line results for NIAID-funded Entolimod efficacy study expected in early December. Company briefed Pentagon and BARDA officials in April and May 2026 respectively. Entolimod received FDA Fast Track and Orphan Drug designations for acute radiation syndrome.
Yesterday
6Nov
Valion Bio President and CFO Lisa Wolf to resign effective Dec 11
Lisa Wolf resigns as President, COO, and CFO of Valion Bio Inc. Resignation is effective December 11. Announcement made via SEC filing.
7 days ago
15Oct
Valion Bio subsidiary completes feasibility test of LarmorBio platform
Velocity Bioworks, a Valion Bio subsidiary, completed an initial feasibility evaluation of LarmorBio's BioScan-NMR platform. The evaluation confirmed that nuclear magnetic resonance measurements can track microbial growth during fermentation. LarmorBio is developing a real-time continuous monitoring platform to reduce batch failure risks and lower manufacturing costs.
28 days ago
14Oct
Valion Bio promotes domestic CDMO capacity amid Section 232 tariffs
Valion Bio highlights Velocity Bioworks' domestic manufacturing capabilities. Section 232 tariffs impose up to 100% duty on certain imported pharmaceuticals. Velocity Bioworks offers microbial manufacturing up to 200 liters. Framework effective September 29, 2026, drives focus on US-based supply chains.
